Back to search
FDAFDA · Food and drugs·Recall number D-0653-2022

hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61

Published March 23, 2022 · Recall initiated: February 24, 2022

Summary

FDA records drug Class II recall D-0653-2022, published March 23, 2022 and initiated February 24, 2022. Recalling firm: The Harvard Drug Group; Status: Terminated; Reported quantity: 5,953 cartons; Lot: Lot #: T03755, T03756, Exp. Date 03/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out of specification result obtained during routine stability testing for Impurities.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Harvard Drug Group
Distributor
Nationwide within USA
Lot
Lot #: T03755, T03756, Exp. Date 03/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was hydrALAZINE HCl Tablets, USP, 10 mg, 100 Tablets per carton (10x10 blister packs), Rx only, Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152 USA. NDC # 0904-6440-61 recalled?

Yes. FDA published recall D-0653-2022 on March 23, 2022. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification result obtained during routine stability testing for Impurities.

What should I do if I have this product?

Voluntary: Firm initiated · Letter